Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
US11845805B2 · kind B2 · utility
0Cited by
30References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2021 |
| Grant date | Dec 19, 2023 |
| Priority date | — |
| Expiry date | Dec 21, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.